SABCS 2021 Monitoring ESR1 Mutations May Optimize Treatment in Metastatic Breast Cancer Publish Date December 13, 2021 Monitoring bESR1mut enabled optimization of the endocrine therapy used with a CDK4/6 inhibitor.
SABCS 2021 Elacestrant Improved PFS in Metastatic Breast Cancer Progressing on CDK4/6 Therapy Publish Date December 9, 2021 Elacestrant showed a statistically significant and clinically meaningful progression-free survival improvement compared with standard of care.